axicabtagene ciloleucel,fludarabine,cyclophosphamide
gilead
['zuma-7', 'axi-cel', 'lymphoma']
late breaking at #asco23: in the phase 3 zuma-7 trial, patients with relapsed or refractory large b-cell lymphoma who received axi-cel (cd19-specific car t cells) had a 27.4% lower risk of death than patients who received standard therapy. full trial results:
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.